EG 427

EG427 is a French biotechnology company that has pioneered a new gene therapy approach called precision gene therapy. By leveraging the natural properties of herpes simplex virus type 1 (HSV-1), particularly its ability to establish lifelong latency in peripheral neurons, EG 427 ensures highly specific and long-lasting transgene expression, offering a long-term treatment for patients with severe, chronic, and localized diseases, starting with peripheral nervous system disorders.